The Ocular Hypertension drugs in development market research report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ocular Hypertension. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued products.
GlobalData tracks 48 drugs in development for Ocular Hypertension by 37 companies/universities/institutes. The top development phase for Ocular Hypertension is phase ii with 18 drugs in that stage. The Ocular Hypertension pipeline has 45 drugs in development by companies and three by universities/ institutes. Some of the companies in the Ocular Hypertension pipeline products market are: NicOx, Santen Pharmaceutical and Laboratoires Thea.
The key targets in the Ocular Hypertension pipeline products market include Prostaglandin F2 Alpha Receptor, Beta 1 Adrenergic Receptor, and Beta 2 Adrenergic Receptor.
The key mechanisms of action in the Ocular Hypertension pipeline product include Prostaglandin F2 Alpha Receptor Agonist with 15 drugs in Pre-Registration. The Ocular Hypertension pipeline products include seven routes of administration with the top ROA being Ophthalmic and three key molecule types in the Ocular Hypertension pipeline products market including Small Molecule, and Gene Therapy.
Ocular Hypertension overview
Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea, and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.
For a complete picture of Ocular Hypertension’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
